by Samby S, Besson D, Dutta A, Patra B, Doy A, Glossop P, Mills J, Whitlock G, Hooft van Huijsduijnen R, Monaco A, Bilbe G, Mowbray C, Perry B, Adam A, Wells TNC, and Willis PA. ACS Infectious Diseases 2022, 8(4): 713–720. doi: 10.1021/acsinfecdis.1c00527
Summary: The COVID-19 pandemic has underlined the need to invest in the search for new medicines targeting emerging threats. An initial response is to reposition currently approved drugs, but a more targeted approach is subsequently needed. Following the successful deployment and uptake of previous open access compound collections, MMV (Medicines for Malaria venture), and DNDi have collaborated to assemble the Pandemic Response Box, a collection of 400 compounds to facilitate drug discovery in emerging infectious disease. The selection has been made by medicinal chemistry experts, based on public domain information on chemotypes currently in discovery and early development. The compounds are freely available as a pharmacological test set on the understanding that data will be shared rapidly in the public domain.
